Cardiac fibrosis: Pathobiology and therapeutic targets

Area of Science:

• Cardiovascular Biology
• Cellular Biology
• Pathology

Background:

• Cardiac fibrosis, characterized by myocardial extracellular matrix accumulation, is a critical factor in heart disease progression, leading to arrhythmias and heart failure.
• Current therapeutic strategies do not directly target the extracellular matrix, highlighting an unmet clinical need to manage fibrotic remodeling.
• Identifying specific markers for cardiac fibroblasts, the key cells regulating extracellular matrix turnover, has been a significant challenge in fibrosis research.

Discussion:

• Recent lineage tracing and single-cell RNA sequencing studies have illuminated the diverse origins and heterogeneity of cardiac fibroblasts.
• Understanding the molecular pathways that activate fibroblasts during cardiac remodeling, both ischemic and non-ischemic, is crucial for developing effective interventions.
• Investigating the intercellular communication between fibroblasts and other cardiac and inflammatory cells offers potential avenues for novel therapeutic strategies.

Key Insights:

• Cardiac fibroblasts are central to myocardial extracellular matrix regulation and fibrotic processes.
• Novel insights into fibroblast heterogeneity and activation pathways are emerging from advanced single-cell analyses.
• Targeting fibroblast activation and communication presents a promising strategy for treating cardiac fibrosis.

Outlook:

• Future research should focus on validating identified fibroblast markers and therapeutic targets in preclinical and clinical settings.
• Developing therapies that modulate fibroblast behavior could slow or reverse cardiac fibrosis and improve patient outcomes.
• Continued investigation into the complex cellular and molecular mechanisms underlying cardiac fibrosis is essential for advancing treatment options.